在2型糖尿病中,单独使用达帕格利弗洛辛或与埃克西纳提德联合治疗期间,β细胞功能和胰岛素敏感性的变化
Curtis Triplitt1,2, Eugenio Cersosimo1,2, Mariam Alatrach1,2
1Division of Diabetes, Department of Medicine, University of Texas Health Science Center, San Antonio, TX.
-葡萄糖共运输体2抑制剂 (SGLT2is) 和类似葡萄糖素的1受体激动剂 (GLP-1RAs) 改善了2型糖尿病中的β细胞功能. 与SGLT2is和GLP-1RAs的联合治疗显示出β细胞功能和胰岛素敏感性的优异改善.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2D) 的特征是β细胞功能受损 (BCF).
- -葡萄糖共运输体2抑制剂 (SGLT2is) 和类似葡萄糖1受体激动剂 (GLP-1RAs) 越来越多地用于T2D管理.
- SGLT2is和GLP-1RAs对BCF的联合作用需要进一步研究.
研究的目的:
- 评估SGLT2is和GLP-1RAs单独或组合对T2D患者的BCF的影响.
- 测试组合疗法提供优越的BCF改善与单疗法相比的假设.
主要方法:
- 90名患有T2D的患者参加了急性口服葡萄糖耐受性测试 (OGTT) 和1个月和4个月的治疗.
- 药物包括安慰剂,达巴格利弗洛辛 (SGLT2i),异胺 (GLP-1RA) 和达巴格利弗洛辛/异胺组合.
- 计算的指数包括修正的松达指数 (cMI),胰岛素分泌和BCF.
主要成果:
- 经过急性治疗,达帕格利弗洛辛,埃克萨纳提德和组合疗法与安慰剂的CMI增加.
- 经过1个月和4个月后,cMI仍然在埃克萨纳提德上升,并且在达帕格利弗洛辛和组合治疗中进一步增加.
- 与达帕格利弗洛辛和安慰剂相比,在埃克萨纳提德和联合治疗时,胰岛素分泌量更高.
- 随着急性和随访时的达帕格利弗洛辛,埃克萨纳提德和组合治疗,BCF指数显著增加,组合显示出最大效果.
结论:
- 达帕格利弗洛辛和埃克萨纳提德单一治疗都导致BCF和胰岛素敏感性的持续改善.
- 与达帕格利弗洛辛和埃克萨纳提德的联合治疗显著增强了BCF和胰岛素敏感性,超过单独使用任何一种药物的效果.
更多相关视频
08:50Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets
Published on: July 3, 2018
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
